Toggle menu

HighSTEACS

Start date:
June 2014
End date:
March 2017
Co-ordinated by:
University of Edinburgh & NHS Lothian

HighSTEACS is a randomised controlled trial, across 10 hospitals in NHS Lothian and NHS Greater Glasgow & Clyde, assessing patient outcomes before and after the implementation of high sensitivity Troponin assay

Research Team

EMERGE Research team
Cardiology Research Group

Aim

HighSTEACS is a randomised controlled trial, across 10 hospitals in NHS Lothian and NHS Greater Glasgow & Clyde, assessing patient outcomes before and after the implementation of high sensitivity Troponin assay. The primary endpoint is the one-year rate of cardiovascular death or recurrent myocardial infarction. Secondary endpoints include length of stay, unplanned coronary revascularisation, recurrent hospital admissions excluding ACS, bleeding events and non-cardiovascular death.  There is also a sub-study at the ED, RIE and in one site in NHS Greater Glasgow and Clyde.

Trial Design

Prospective stepped wedge cluster randomised controlled trial

Eligibility criteria (summary)

Patients who present to the Emergency Department with suspected heart disease

Chief Investigator

Professor Nick Mills

Chair of Cardiology

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Rachel O'Brien

Lead Research Nurse

Hedda Nyhus

Senior Research Nurse

Bev Goldberg

AMU Senior Research Nurse

Megan McGrath

Senior Research Nurse

More EMERGE Trials

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Assisting in identifying patients with Humeral shaft fractures in the ED by screening.

Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.

Read more

HU-FIX

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)